Radiant Genomics, Inc.

Biotech · Private

Integrated enzyme discovery platform combining metagenomic sequence database, search engine, clone library, and automated gene recovery system

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · radiantgenomics.com

Sector: Biotech
Total capital: $4.4M

Federal grants: $4.3M; 8 awards · 2015–2017; Rank in peer group#12 of 36
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $63K; 1 award · Defense; Rank in Biotech#349 of 4373
Granted patents: 0; 4 pending

Capital timeline

Latest events

Mar 2017Federal grantHealth and Human S · Phase II · A Web-Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation$542K
Aug 2016Federal grantDefense · Phase I · Exploiting Microbiome and Synthetic Biology to Discover and Produce Naturally Occurring Antibiotics$150K
Aug 2016Federal contractDefense · Igf::ot::igf C152-004-0089 SBIR Phase I$63K
Apr 2016Federal grantHealth and Human S · Phase II · A Web Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation$1.3M
Apr 2016Federal grantHealth and Human S · Phase I · A Web-Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation$966K
Mar 2016Federal grantHealth and Human S · Phase II · A Web-Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation$749K
Jul 2015Federal grantHealth and Human S · Phase I · High-throughput SARP-mediated activation of silent gene clusters to produce novel natural products$216K

Show 2 earlier federal awards

Mar 2015Federal grantHealth and Human S · Phase I · Engineered Actinomycete Production Hosts for Heterologous Natural Product Discovery$215K
Feb 2015Federal grantHealth and Human S · Phase I · A Metagenomic Platform to Identify Amphotericin B Analogs$205K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 36 peers

Line = median

Biotech · Platform

Federal grants#12 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 4

Dec 10, 2015PendingCompositions and Methods for Targeted Gene Disruption in ProkaryotesUSPTOApplication 14836101
May 14, 2015PendingCompositions And Methods For Targeted Gene Disruption In ProkaryotesUSPTOApplication 14537940
PendingCompositions And Methods For Activating Silent Gene ClustersUSPTOApplication PCTUS2016034723

Show all 4 patent records

Compositions and Methods for Targeted Gene Disruption in ProkaryotesDec 10, 2015 · Application 14836101Pending
Compositions And Methods For Targeted Gene Disruption In ProkaryotesMay 14, 2015 · Application 14537940Pending
Compositions And Methods For Activating Silent Gene ClustersApplication PCTUS2016034723Pending
Compositions And Methods For Activating Silent Gene ClustersApplication 62168631Pending

Abpro CorpSimilar federal contract value in Biotech · $66K in contracts
RETROTHERAPY, LLCSimilar federal contract value in Biotech · $65K in contracts
CELLULAR RESEARCH, INC.Similar federal contract value in Biotech · $63K in contracts
LEADSCOPE, INC.Similar federal contract value in Biotech · $62K in contracts
Emmaus Life Sciences, Inc.Similar federal contract value in Biotech · $60K in contracts
Transposagen Biopharmaceuticals, Inc.Similar federal contract value in Biotech · $56K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.